转化生长因子-β受体突变和儿童肺动脉高血压
Rachel E Harrison1, Rolf Berger, Sheila G Haworth
1Division of Medical Genetics, University of Leicester, Leicester, UK.
Circulation
|February 3, 2005
概括
转化生长因子β受体的遗传突变是儿童肺动脉高血压 (PAH) 的关键原因. 早期发病的PAH,特别是异常性PAH,通常涉及这些遗传缺陷,突出显示异质病因.
科学领域:
- 儿科心脏病学 儿科心脏病学
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的血管疾病.
- 成年人PAH与BMPR2和ALK-1基因突变有关.
- 儿童PAH可能是异常性或与先天性心脏病相关.
研究的目的:
- 调查儿童早期发病的PAH的遗传原因.
- 分析转化生长因子-β信号通路基因中的突变.
- 确定遗传缺陷在儿童PAH中的作用.
主要方法:
- 在患有PAH的18名儿童 (<6岁) 中,对TGF-β通路基因的突变分析.
- 对BMPR2,ALK-1和内分泌蛋白进行基因检测.
- 临床数据审查,以展示特征和疾病进展.
主要成果:
- 在22%的PAH儿童中发现了生殖系突变.
- BMPR2突变 (11%) 包括新删除和无意义突变.
- ALK-1和内分泌蛋白突变也被确定在异形性PAH病例中.
- 基于突变状态的临床特征没有明确的区别.
结论:
- 儿童PAH具有异质的遗传基础.
- 转化生长因子β受体的遗传缺陷在儿童PAH中至关重要.
- 基因检测对于了解早期发病的PAH病因很重要.
相关概念视频
TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


